Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous Tumor Antigens (ATA)
- Development stage
- Preclinical
- Lead developer
- RGCC
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
Autologous Tumor Antigens (ATA) is a personalized cancer immunotherapy developed by the Research Genetic Cancer Centre Group (RGCC). The therapy utilizes cellular fragments—including organelles, mitochondria, cell membranes, RNA, DNA, and protein fragments—derived from dying circulating tumor cells (CTCs) isolated from the patient's own blood. These fragments serve as a source of patient-specific tumor-associated antigens (TAAs). When administered as a vaccine, ATA is designed to stimulate the patient's immune system to recognize and destroy cancer cells, aiming to inhibit tumor growth and prevent recurrence. It is intended for use in various solid tumors, such as breast, lung, prostate, colorectal, and ovarian cancers, but is not indicated for hematologic malignancies.
- Brand names
- ATA
- Other names
- Autologous Tumor Antigens PrepRGCC ATA
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)Neoantigen-specific T-cell receptor
Beyond the preview
Go deeper on Autologous Tumor Antigens (ATA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous Tumor Antigens (ATA).